These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3092623)

  • 21. Safety and efficacy of encainide for malignant ventricular arrhythmias.
    Tordjman T; Podrid PJ; Raeder E; Lown B
    Am J Cardiol; 1986 Aug; 58(5):87C-95C. PubMed ID: 3092625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
    Slater W; Lampert S; Podrid PJ; Lown B
    Am J Cardiol; 1988 Feb; 61(4):349-53. PubMed ID: 3124591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction. The Encainide-Ventricular Tachycardia Study Group.
    Am J Cardiol; 1988 Sep; 62(9):571-5. PubMed ID: 3137797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide.
    Gomoll AW; Byrne JE; Antonaccio MJ
    Am J Cardiol; 1986 Aug; 58(5):10C-17C. PubMed ID: 3092614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.
    Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ
    Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
    Harrison DC; Kates RE; Quart BD
    Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant ventricular tachyarrhythmias associated with the use of encainide.
    Winkle RA; Mason JW; Griffin JC; Ross D
    Am Heart J; 1981 Nov; 102(5):857-64. PubMed ID: 6795909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of encainide for the treatment of ventricular arrhythmias.
    Soyka LF
    Am J Cardiol; 1986 Aug; 58(5):96C-103C. PubMed ID: 3092626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiology in assessing supraventricular arrhythmias: value of programmed stimulation in predicting and understanding efficacy of encainide.
    Wellens HJ; Brugada P
    Am J Cardiol; 1986 Aug; 58(5):37C-40C. PubMed ID: 3092617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
    Winkle RA; Peters F; Kates RE; Harrison DC
    Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Encainide. A review of its pharmacological properties and therapeutic efficacy.
    Brogden RN; Todd PA
    Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flecainide versus quinidine: results of a multicenter trial.
    Hodges M; Salerno DM; Granrud G
    Am J Cardiol; 1984 Feb; 53(5):66B-71B. PubMed ID: 6364770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute intravenous and long-term oral hemodynamic effects of encainide.
    Sami MH
    Am J Cardiol; 1986 Aug; 58(5):25C-30C. PubMed ID: 3092616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short- and long-term therapeutic efficacy of quinidine sulfate for the treatment of chronic ventricular arrhythmias.
    Panidis I; Morganroth J
    J Clin Pharmacol; 1982; 22(8-9):379-84. PubMed ID: 6752212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function.
    Sami MH; Derbekyan VA; Lisbona R
    Am J Cardiol; 1983 Sep; 52(5):507-11. PubMed ID: 6412535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias.
    Morganroth J; Horowitz LN
    Am J Cardiol; 1985 Oct; 56(10):585-7. PubMed ID: 3901720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encainide: a new and potent antiarrhythmic agent.
    Harrison DC; Winkle R; Sami M; Mason J
    Am Heart J; 1980 Dec; 100(6 Pt 2):1046-54. PubMed ID: 6778194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.